Join to View Full Profile
44 Binney StDana-Farber Cancer InstituteBoston, MA 02115
Phone+1 617-632-6629
Fax+1 617-632-5168
Are you Dr. Bradner?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. James Bradner, MD is an oncologist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts. He is an Assistant Professor of Medicine at Dana-Farber Cancer Institute.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2002 - 2005- Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 1999 - 2002
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1999
Certifications & Licensure
MA State Medical License 2002 - 2025
Publications & Presentations
PubMed
- 11 citationsA molecular glue degrader of the WIZ transcription factor for fetal hemoglobin induction.Pamela Y Ting, Sneha Borikar, John Ryan Kerrigan, Noel M Thomsen, Eamon Aghania
Science. 2024-07-05 - Author Correction: Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma.Pawel K Mazur, Alexander Herner, Stephano S Mello, Matthias Wirth, Simone Hausmann
Nature Medicine. 2024-07-01 - 5 citationsAuthor Correction: An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation.George P Souroullas, William R Jeck, Joel S Parker, Jeremy M Simon, Jie-Yu Liu
Nature Medicine. 2024-06-01
Press Mentions
Genetic Study Provides First-Ever Insight into Biological Origin of SchizophreniaJune 25th, 2020- Real-Time Transferrin-Based PET Detects MYC-Positive Prostate CancerJune 7th, 2020
SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in CancerJune 6th, 2019- Join now to see all
